Literature DB >> 20694113

Beyond symptomatic improvement:assessing real-world outcomes in patients with major depressive disorder.

Alan M Langlieb1, Christine J Guico-Pabia.   

Abstract

OBJECTIVE: To quantify the negative impact that major depressive disorder (MDD) has on quality of life, disability, and work, family, and overall psychosocial functioning. Available scales that assess these areas of impairment as they relate to patients with MDD are described. DATA SOURCES: PUBMED SEARCHES WERE CONDUCTED USING THE FOLLOWING TERMS: (MDD OR major depressive disorder) AND (absenteeism OR absente*); AND (quality of life OR QOL); AND (psychosocial function*); AND (presente* OR presenteeism); AND (health care cost* OR [health care] cost*); AND (health outcome*); AND (functional outcome*); AND (family life); AND (disabil* OR disability); AND (work function*); AND (unemployment OR unemploy*). The literature search was conducted in July 2008 and was restricted to English language articles. There were no limits set on the dates of the search. STUDY SELECTION: Two hundred twenty potential articles were identified. Among these studies, 48 presented primary data directly demonstrating the effect of MDD on quality of life, disability, and work, family, and overall psychosocial functioning. DATA EXTRACTION: Primary data were compiled from these studies and are summarily described. Available scales that assess quality of life, disability, and work, family, and overall psychosocial functioning are also described. DATA SYNTHESIS: MDD was found to be associated with significant disability and declines in functioning and quality of life. The Sheehan Disability Scale, the 36-item Short-Form Health Survey, and the Work Limitations Questionnaire were the most commonly used scales according to this review of the literature, but the majority of studies used direct and indirect disability measures, such as health care and other disability-related costs.
CONCLUSIONS: In addition to assessing symptomatic outcomes, physicians should routinely assess their depressed patients on "real-world" outcomes. The development of a concise functional outcome measure specific to MDD is necessary for busy clinical practices.

Entities:  

Year:  2010        PMID: 20694113      PMCID: PMC2911007          DOI: 10.4088/PCC.09r00826blu

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  123 in total

1.  The validity and reproducibility of a work productivity and activity impairment instrument.

Authors:  M C Reilly; A S Zbrozek; E M Dukes
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

2.  The effect of depression on motor function and disease severity of Parkinson's disease.

Authors:  Spiridon Papapetropoulos; John Ellul; Andreas A Argyriou; Elisabeth Chroni; Nicoletta P Lekka
Journal:  Clin Neurol Neurosurg       Date:  2005-09-16       Impact factor: 1.876

3.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

4.  Health-related quality of life among patients with major depression.

Authors:  Simo Saarijärvi; Jouko K Salminen; Tuula Toikka; Raimo Raitasalo
Journal:  Nord J Psychiatry       Date:  2002       Impact factor: 2.202

5.  Diagnosis, treatment, comorbidity, and resource utilization of depressed patients in a general medical practice.

Authors:  M P Luber; J P Hollenberg; P Williams-Russo; T N DiDomenico; B S Meyers; G S Alexopoulos; M E Charlson
Journal:  Int J Psychiatry Med       Date:  2000       Impact factor: 1.210

6.  Recovery from depression, work productivity, and health care costs among primary care patients.

Authors:  G E Simon; D Revicki; J Heiligenstein; L Grothaus; M VonKorff; W J Katon; T R Hylan
Journal:  Gen Hosp Psychiatry       Date:  2000 May-Jun       Impact factor: 3.238

7.  The effect of bipolar I disorder and major depressive disorder on workforce function.

Authors:  R S McIntyre; K Wilkins; H Gilmour; J K Soczynska; J Z Konarksi; A Miranda; H O Woldeyohannes; D Vagic; M Alsuwaidan; S H Kennedy
Journal:  Chronic Dis Can       Date:  2008

8.  Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program.

Authors:  S M Sotsky; D R Glass; M T Shea; P A Pilkonis; J F Collins; I Elkin; J T Watkins; S D Imber; W R Leber; J Moyer
Journal:  Am J Psychiatry       Date:  1991-08       Impact factor: 18.112

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Comorbid depression, chronic pain, and disability in primary care.

Authors:  Bruce A Arnow; Enid M Hunkeler; Christine M Blasey; Janelle Lee; Michael J Constantino; Bruce Fireman; Helena C Kraemer; Robin Dea; Rebecca Robinson; Chris Hayward
Journal:  Psychosom Med       Date:  2006 Mar-Apr       Impact factor: 4.312

View more
  21 in total

Review 1.  The efficacy and tolerability of bupropion in the treatment of major depressive disorder.

Authors:  Ricardo Moreira
Journal:  Clin Drug Investig       Date:  2011-10-19       Impact factor: 2.859

2.  Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up.

Authors:  W W IsHak; J Mirocha; D James; G Tobia; J Vilhauer; H Fakhry; S Pi; E Hanson; R Nashawati; E D Peselow; R M Cohen
Journal:  Acta Psychiatr Scand       Date:  2014-06-23       Impact factor: 6.392

3.  Stressors related to immigration and migration background in Turkish patients with psychiatric disorder: validity of a short questionnaire (MIGSTR10).

Authors:  Matthias Johannes Müller; Eckhardt Koch
Journal:  J Immigr Minor Health       Date:  2011-12

4.  Making assessment locally relevant: measuring functioning for maternal depression in Khayelitsha, Cape Town.

Authors:  Marguerite Schneider; Emily Baron; Thandi Davies; Judith Bass; Crick Lund
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-01-08       Impact factor: 4.328

Review 5.  Pirlindole in the treatment of depression and fibromyalgia syndrome.

Authors:  Jaime C Branco; Ana Maria Tomé; Manuel R Cruz; Augusto Filipe
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

6.  Patient-reported functioning in major depressive disorder.

Authors:  Waguih William IsHak; David M James; James Mirocha; Haidy Youssef; Gabriel Tobia; Sarah Pi; Katherine L Collison; Robert M Cohen
Journal:  Ther Adv Chronic Dis       Date:  2016-03-31       Impact factor: 5.091

7.  Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories.

Authors:  Andrew J Cutler; Carl P Gommoll; Changzheng Chen; William M Greenberg; Adam Ruth
Journal:  Prim Care Companion CNS Disord       Date:  2015-06-11

8.  Study protocol: Hybrid Type I cost-effectiveness and implementation study of interpersonal psychotherapy (IPT) for men and women prisoners with major depression.

Authors:  Jennifer E Johnson; Ted R Miller; Robert L Stout; Caron Zlotnick; Louis A Cerbo; Joel T Andrade; Shannon Wiltsey-Stirman
Journal:  Contemp Clin Trials       Date:  2016-02-01       Impact factor: 2.226

9.  Development of the Global Disability Scale (Glo.Di.S): preliminary results.

Authors:  Konstantinos N Fountoulakis; Eirini Lekka; Evangelia Kouidi; Ioanna Chouvarda; Asterios Deligiannis; Nickolaos Maglaveras
Journal:  Ann Gen Psychiatry       Date:  2012-05-17       Impact factor: 3.455

10.  Multi-modality: a new approach for the treatment of major depressive disorder.

Authors:  Elliott Richelson
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-30       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.